Global Generic Injectables Market Overview:
The latest report published by IMARC Group, titled “Generic Injectables Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” offers a comprehensive analysis of the industry, which comprises insights on the generic injectables market size. The report also includes competitor and regional analysis, and contemporary advancements in the global market. The global generic injectables market size reached US$ 43.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 70.4 Billion by 2028, exhibiting a growth rate (CAGR) of 8.3% during 2023-2028.
Generic injectables are pharmaceutical products that are identical or bioequivalent to the original branded injectable products but are marketed under a different brand name after the patent for the original product expires. They are manufactured using the same active pharmaceutical ingredients as the original product and are typically sold at a lower price than the branded product. They are widely used to treat various medical conditions such as cancer, infectious diseases, and autoimmune disorders. They are used in hospitals, clinics, and other medical facilities and are administered through intravenous, intramuscular, or subcutaneous routes.
Global Generic Injectables Market Trends:
The global market is majorly driven by the increasing demand for affordable healthcare products and services. In line with this, the expiration of patents for many branded injectable products is significantly contributing to the market. Furthermore, the growing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disease is positively influencing the market. Apart from this, the expansion of the global pharmaceutical industry is creating a positive outlook for the market. Moreover, the escalating generic drug utilization and rapid technological advancements in manufacturing processes are catalyzing the market. Besides, the increasing demand for biosimilars is offering numerous opportunities for the market. Additionally, the trend toward personalized medicine is accelerating the development of new injectable treatments that can be customized to individual patient needs.
Global Generic Injectables Market 2023-2028 Analysis and Segmentation
Competitive Landscape with Key Players:
- Hospira (Pfizer)
- Fresenius Kabi
- Sandoz (Novartis)
Also, Read the Full Blog: List of the Top Generic Pharmaceuticals Injectables Companies Worldwide
Breakup by Therapeutic Area:
On the basis of the therapeutic area, the market has been classified into oncology, anesthesia, anti-infectives, parental nutrition and cardiovascular.
Amongst these, the oncology segment holds the largest market share.
Breakup by Container:
Based on the container, the market has been categorized into vials, ampoules, premix, and prefilled syringes.
Breakup by Distribution Channel:
- Retail Pharmacy
Breakup by Region:
Region-wise, North America holds the leading position in the market. Other major regions include Europe, Asia, Middle East and Africa, and Latin America.
TOC for the Generic Injectables Market Research Report:
- Scope and Methodology
- Executive Summary
- Generic Injectables Market SWOT Analysis
- Value Chain Analysis
- Price Analysis
- Competitive Landscape
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St. Brooklyn, NY 11249, USA
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800